Live Breaking News & Updates on European Medicinal Authority

Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd
The upcoming Phase III trial with Diamyd
in new-onset type 1 diabetes will be based on the first precision medicine approach in the field. The trial is designed to confirm the effect and safety of Diamyd
in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.
The Phase III trial is designed to enroll approximately 330 individuals aged 12 to 28, recently diagnosed with type 1 diabetes, who carry the HLA DR3-DQ2 haplotype. This patient population is based on clinical efficacy and safety results from the Phase IIa and Phase IIb trials DIAGNODE-1 and DIAGNODE-2, as well as the large-scale meta-analysis encompassing data from more than 600 individuals from previous Phase II and Phase III trials using Diamyd ....

United States , Uppsala Lan , Ulf Hannelius , European Medicinal Authority , Health Technology Assesment , Drug Administration , Company European Phase Iib , Company Certified Adviser , Uppsala University Hospital , United States Food , European Phase , Uppsala University , Diamyd Medical , Nextcell Pharma , Nasdaq First North Growth Market , Certified Adviser , ஒன்றுபட்டது மாநிலங்களில் , ஐரோப்பிய மருத்துவ அதிகாரம் , ஆரோக்கியம் தொழில்நுட்பம் மதிப்பீடு , நிறுவனம் ஐரோப்பிய கட்டம் இயைப் , ஒன்றுபட்டது மாநிலங்களில் உணவு , ஐரோப்பிய கட்டம் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை , நீரிழிவு நோய் ,